Early shift from ranibizumab to aflibercept for resistant pigment epitelial detachment in classical choroidal neovascularization
10.3980/j.issn.1672-5123.2017.10.03
- VernacularTitle:阿柏西普治疗雷珠单抗效果不佳的CNV伴难治性色素上皮脱离的疗效
- Author:
Ozkan, SEVER
;
Fatih HOROZOGLU
- Keywords:
aflibercept;
suboptimal response;
resistance;
choroidal neovascularization;
early
- From:
International Eye Science
2017;17(10):1812-1816
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To evaluate the therapeutic effect of aflibercept in patients with suboptimal response to ranibizumab therapy in the early period. ·METHOD: Thirty-eight patients with wet type agerelated macular degeneration( W-AMD) were involved in this study. Eighteen patients with suboptimal response were shifted to 3 doses monthly intravitreal aflibercept therapy ( IVA ) and left 20 patients with suboptimal response went on 3 more monthly intravitreal ranibizumab ( IVR ) . All changes were evaluated with fluorescein anigography ( FA ) and optical coherence tomography ( OCT) . ·RESULTS: Preoperative mean visual acuity ( VA ) and central macular thickness ( CMT) of patients were 0. 84 ± 0. 47 logMAR and 360 ± 84 μm, respectively. One month after last IVR and IVA treatments, VA of patients were 1.1±0.34 (P=0. 11) logMAR and 0. 48±0. 37 (P=0. 019) logMAR and CMTs were 300±79 μm (P=0. 002) and 271± 51 μm (P=0. 002), respectively. · CONCLUSION: To eliminate repeated therapy for patients with suboptimal response to ranibizumab therapy, aflibercept might be a good alternative for early visual rehabilitation.
